The Clinical Effects of Lamivudine and Adefovir Dipivoxil in Treatment of Hepatic B Liver Cirrhosis in Decompensated Period

Objective:To evaluate the clinical efficacy and safety of lamivudine and adefovir dipivoxil in treatment of hepatic B liver cirrhosis in decompensated period. Method:Fifty-six patients with hepatic B liver cirrhosis in decompensated period in the hospital from June 2012 to May 2013 were randomly divided into the experimental group and the control group. All the patients were given the treatment of normal liver protection, such as diuresis and albumin supplementation. In addition, the experimental group was given lamivudine and adefovir dipivoxil, the control group was only given lamivudine.The adverse events would be recorded during the study after treatment of 24 weeks. The clinical curative effects of two groups were observed and compared. Result:After treatment, AST, ALT, total bilirubin levels of both groups were significantly declined, there were all significant difference compared with before treatment(P0.05). And the experimental group after treatment of AST, ALT, total bilirubin levels were lower than the control group, and the difference between the two groups were all statistically significant(P0.05). The Child-Pugh score were decrease as the extension of treatment time in two groups, and the experimental group decreased more obvious than the control group. The difference of Child-Pugh score after treatment 24 weeks between the two groups was statistically significant(P0.05). The negative conversion ratio of HBV-DNA of the control group was 38.46% while the treatment group was 51.85% after treatment, so the clinical effect of the treatment group was better than the control group. Conclusion:Lamivudine combined with adefovir dipivoxil in treatment of hepatic B liver cirrhosis in decompensated period has good clinical curative effects. It has highly safety, worthy of clinical popularization and application.